{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T15:41:34Z","timestamp":1791733294188,"version":"4.3.4"},"reference-count":32,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2020,6,30]]},"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21) is one of the members of endocrine arm of FGF family. Its actions as a glucose and lipids metabolism regulator are widely known. Although the mechanism of FGF21 action in kidneys is still under investigation, FGF21 was considered as a marker of early kidney function decline. While many researchers focused on adult subjects in this matter, there are no data regarding children. Therefore, we have investigated the relationship between plasma or urine FGF21 levels and kidney function in a group of 42 pediatric patients with chronic kidney disease (CKD). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed. The concentration of FGF21 in serum and urine was determined by enzyme immunoassay. The results revealed significantly higher serum FGF21 concentration among children from CKD group. However, serum FGF21 level was not related to gender, proteinuria, eGFR or renal replacement therapy. Urine FGF21 concentration correlated negatively with albuminuria and positively with eGFR. Documented negative correlation of FGF21 fractional excretion and eGFR is not enough to support the role of FGF21 as a biomarker for predicting kidney disease progression in children and adolescents. Other mechanisms including local kidney FGF21 production or enhanced excretion due to higher extrarenal production may result in higher urine FGF21 concentrations.<\/jats:p>","DOI":"10.33549\/physiolres.934307","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:49:21Z","timestamp":1596196161000},"page":"451-460","source":"Crossref","is-referenced-by-count":6,"title":["Fibroblast Growth Factor 21 (FGF21) in Children and Adolescents With Chronic Kidney Disease"],"prefix":"10.33549","author":[{"given":"Z","family":"GAMROT","sequence":"first","affiliation":[{"name":"Unit of Paediatric Hematology and Oncology, Chorzow City Hospital, Chorzow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"ADAMCZYK","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"\u015aWI\u0118TOCHOWSKA","sequence":"additional","affiliation":[{"name":"Chair and Department of Medical and Molecular Biology, The School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"ROSZKOWSKA-BJANID","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Ward, Public Clinical Hospital No. 1 in Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"GAMROT","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Society, Department of Pediatrics, The School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"SZCZEPA\u0143SKA","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ADAMS AC, CHENG CC, COSKUN T, KHARITONENKOV A: FGF21 requires \u03b2klotho to act in vivo. PLoS One 7: e49977, 2012. https:\/\/doi.org\/10.1371\/journal.pone.0049977","DOI":"10.1371\/journal.pone.0049977"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"ANDERSEN B, BECK-NIELSEN H, H\u00d8JLUND K: Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 75: 514-519, 2011. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04084.x","DOI":"10.1111\/j.1365-2265.2011.04084.x"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"ANGELIN B, LARSSON TE, RUDLING M: Circulating fibroblast growth factors as metabolic regulators\u2014a critical appraisal. Cell Metab 16: 693-705, 2012. https:\/\/doi.org\/10.1016\/j.cmet.2012.11.001","DOI":"10.1016\/j.cmet.2012.11.001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ANUWATMATEE S, TANG S, WU B, RYE K-A, ONG K: Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta 489: 196-202, 2019. https:\/\/doi.org\/10.1016\/j.cca.2017.11.002","DOI":"10.1016\/j.cca.2017.11.002"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"ANUWATMATEE S, ALLISON M, SHLIPAK M, MCCLELLAND R, KRAMER H, TANG S, HOU L, RYE K, ONG K: Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. Nephrol Dial Transplant 34: 1009-1016, 2019. https:\/\/doi.org\/10.1093\/ndt\/gfy120","DOI":"10.1093\/ndt\/gfy120"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"BAEK J, NAM HK, RHIE YJ, LEE KH: Serum FGF21 levels in obese Korean children and adolescents. J Obes Metab Syndr 26: 204-209, 2017. https:\/\/doi.org\/10.7570\/jomes.2017.26.3.204","DOI":"10.7570\/jomes.2017.26.3.204"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"BISGAARS A, S\u00d8RENSEN K, JOHANNSEN T, HELGE J, ANDERSSON AM, JUUL A: Significant gender difference in serum levels of fibroblast factor 21 in Danish children and adolescents. Int J Pediatr Endocrinol 2014: 7, 2014. https:\/\/doi.org\/10.1186\/1687-9856-2014-7","DOI":"10.1186\/1687-9856-2014-7"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"CRASTO C, SEMBA R, SUN K, FERRUCCI L: Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc 60: 792-793, 2012. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03879.x","DOI":"10.1111\/j.1532-5415.2011.03879.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"CRUMP C, SUNDQUIST J, WINKLEBY MA, SUNDQUIST K: Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. BMJ 365: l1346, 2019. https:\/\/doi.org\/10.1136\/bmj.l1346","DOI":"10.1136\/bmj.l1346"},{"key":"ref9","unstructured":"CZARNIAK P, KR\u00d3L E, SZCZE\u015aNIAK P: Wybrane aspekty epidemiologiczne przewlek\u0142ej choroby nerek u dzieci i m\u0142odzie\u017cy. (In Polish) Forum Nefrol 1: 45-50, 2010."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"GOSPODAROWICZ D: Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 250: 2515-2520, 1975.","DOI":"10.1016\/S0021-9258(19)41631-1"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"HARAMBAT J, STRALEN KJ, KIM JJ, TIZARD EJ: Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27: 363-373, 2012. https:\/\/doi.org\/10.1007\/s00467-011-1939-1","DOI":"10.1007\/s00467-011-1939-1"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"HINDRICKS J, EBERT T, BACHMANN A, KRALISCH S, L\u00d6SSNER U, KRATZSCH J, STOLZENBURG JU, DIETEL A, BEIGE J, ANDERS M, BAST I, BL\u00dcHER M, STUMVOLL M, FASSHAUER M: Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf) 80: 918-924, 2014. https:\/\/doi.org\/10.1111\/cen.12380","DOI":"10.1111\/cen.12380"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"INAGAKI T: Research perspectives on the regulation and physiological functions of FGF21 and its association with NAFLD. Front Endocrinol (Lausanne) 6: 147, 2015. https:\/\/doi.org\/10.3389\/fendo.2015.00147","DOI":"10.3389\/fendo.2015.00147"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"INAGAKI T, LIN VY, GOETZ R, MOHAMMADI M, MANGELSDORF D, KLIEWER S: Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 8: 77-83, 2008. https:\/\/doi.org\/10.1016\/j.cmet.2008.05.006","DOI":"10.1016\/j.cmet.2008.05.006"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"ITOH N: Hormone-like (endocrine) FGFs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1-11, 2010. https:\/\/doi.org\/10.1007\/s00441-010-1024-2","DOI":"10.1007\/s00441-010-1024-2"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"ITOH N, OHTA H, KONISHI M: Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol 6: 154, 2015. https:\/\/doi.org\/10.3389\/fendo.2015.00154","DOI":"10.3389\/fendo.2015.00154"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"KHARITONENKOV A, DI MARCHI R: FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metab 26: 608-617, 2015. https:\/\/doi.org\/10.1016\/j.tem.2015.09.007","DOI":"10.1016\/j.tem.2015.09.007"},{"key":"ref18","unstructured":"KDIGO 2012 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 3: 19-62, 2013."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"KOHARA M, MASUDA T, SHIIZAKI K, AKIMOTO T, WATANABE Y, HONMA S, SEKIGUCHI C, MIYAZAWA Y, KUSANO E, KANDA Y, ASANO Y, KURO-O M, NAGATA D: Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One 12: e0178971, 2017. https:\/\/doi.org\/10.1371\/journal.pone.0178971","DOI":"10.1371\/journal.pone.0178971"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"KOKKINOS J, TANG S, RYE KA, ONG KL: The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis 257: 259-265, 2017. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.11.033","DOI":"10.1016\/j.atherosclerosis.2016.11.033"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"KOSOLA S, LAMPELA H, GYLLING H, JALANKO H, NISSINEN MJ, LAURONEN J, M\u00c4KISALO H, VAARALAHTI K, MIETTINEN TA, RAIVIO T, PAKARINEN MP: Cholesterol metabolism altered and FGF21 levels high after pediatric liver transplantation despite normal serum lipids. Am J Transplant 12: 2815-2824, 2012. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04147.x","DOI":"10.1111\/j.1600-6143.2012.04147.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"KREJCI E, PESEVSKI Z, NANKA O, SEDMERA D: Physiological role of FGF signaling in growth and remodeling of developing cardiovascular system. Physiol Res 65: 425-435, 2016. https:\/\/doi.org\/10.33549\/physiolres.93321","DOI":"10.33549\/physiolres.933216"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"LEE CH, HUI EY, WOO YC, YEUNG CY, CHOW WS, YUEN MM, FONG CH, XU A, LAM KS: Circulating fibroblast factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metabol 100: 1368-1375, 2015. https:\/\/doi.org\/10.1210\/jc.2014-3465","DOI":"10.1210\/jc.2014-3465"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"LIANG Q, ZHONG L, ZHANG J, WANG Y, BORNSTEIN SR, TRIGGLE CR, DING H, LAM KS, XU A: FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63: 4064-4075, 2014. https:\/\/doi.org\/10.2337\/db14-0541","DOI":"10.2337\/db14-0541"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"LIU JJ, FOO JP, LIU S, LIM SC: The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective. Diabetes Res Clin Pract 108: 382-389, 2015. https:\/\/doi.org\/10.1016\/j.diabres.2015.02.032","DOI":"10.1016\/j.diabres.2015.02.032"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"MIAN AN, SCHWARTZ GJ: Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis 24: 348-356, 2017. https:\/\/doi.org\/10.1053\/j.ackd.2017.09.011","DOI":"10.1053\/j.ackd.2017.09.011"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"ORNITZ DM, ITOH N: The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4: 215-266, 2015. https:\/\/doi.org\/10.1002\/wdev.176","DOI":"10.1002\/wdev.176"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"SUASSUNA PG, DE PAULA R, SANDERS-PINHEIRO H, MOE O, HU M-C: Fibroblast growth factor 21 in chronic kidney disease. J Nephrol 32: 365-377, 2018. https:\/\/doi.org\/10.1007\/s40620-018-0550-y","DOI":"10.1007\/s40620-018-0550-y"},{"key":"ref29","unstructured":"SZYMCZYK A, KRZYWA\u0143SKI R, FORMA E: Struktura i funkcja bia\u0142ak \u03b2Klotho. (In Polish) Folia Medica Lodz 40: 99-132, 2013."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"WARADY BA, CHADHA V: Chronic kidney disease in children: the global perspective. Pediatr Nephrol 22: 1999-2009, 2007. https:\/\/doi.org\/10.1007\/s00467-006-0410-1","DOI":"10.1007\/s00467-006-0410-1"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"ZHANG J, WU H, MA S, JING F, YU C, GAO L, ZHAO J: Transcription regulators and hormones involved in the development of brown fat and white fat browning: transcriptional and hormonal control of brown\/beige fat development. Physiol Res 67: 347-362, 2018. https:\/\/doi.org\/10.33549\/physiolres.933650","DOI":"10.33549\/physiolres.933650"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T12:11:56Z","timestamp":1616847116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2020\/69_451.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":32,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934307","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}